Key PointsThe average pharmaceutical stock yields 1.4%, while Bristol Myers Squibb yields 4%.

Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors

Key PointsBristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances.

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Key PointsPfizer and Bristol Myers Squibb have faced similar challenges, and both are slowly overcoming their obstacles.

3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market

Key PointsAbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products.

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

Key PointsBristol Myers Squibb’s Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company’s 7% revenue gain to $13.1 billion.

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Key PointsConsumer goods giant Procter & Gamble’s sheer size is a proven competitive edge.

3 Magnificent Dividend Stocks for Risk-Averse Investors

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company News